LeonaBio Inc. is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. Its lead drug candidates include lasofoxifene and ATH-1105. LeonaBio Inc., formerly known as Athira Pharma Inc., is headquartered in the Seattle, Washington.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-96.94M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.84 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -107.06% |
| Return on Assets (Trailing 12 Months) | -89.89% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.70 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.60 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.68 |
| Earnings per Share (Most Recent Fiscal Year) | $-25.20 |
| Diluted Earnings per Share (Trailing 12 Months) | $-9.68 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 3.94M |
| Free Float | 2.96M |
| Market Capitalization | $22.56M |
| Average Volume (Last 20 Days) | 0.05M |
| Beta (Past 60 Months) | 2.68 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 25.07% |
| Percentage Held By Institutions (Latest 13F Reports) | 57.12% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |